Andrew Oxtoby
Director/Board Member chez Damien Center
Profil
Andrew Oxtoby is currently the Director at Damien Center.
Previously, he served as the President & Chief Executive Officer at Aimmune Therapeutics, Inc. and as the VP-US Diabetes Sales, Connected Care & Insulins at Eli Lilly & Co. from 2015 to 2019.
He also held the position of General Manager at Lilly Nederland Holding BV from 2009 to 2012.
In addition, Mr. Oxtoby will be the Chief Commercial Officer at Chinook Therapeutics, Inc. in 2023.
He obtained his undergraduate degree from Purdue University in 1996 and an MBA from Harvard Business School in 2002.
Postes actifs de Andrew Oxtoby
| Sociétés | Poste | Début |
|---|---|---|
| Damien Center | Director/Board Member | - |
Anciens postes connus de Andrew Oxtoby
| Sociétés | Poste | Fin |
|---|---|---|
| CHINOOK THERAPEUTICS, INC. | Corporate Officer/Principal | 09/08/2023 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01/01/2019 |
Lilly Nederland Holding BV
 Lilly Nederland Holding BV Financial ConglomeratesFinance Part of Eli Lilly & Co., Lilly Nederland Holding BV provides investment services. The private company is based in Utrecht, Netherlands. | Corporate Officer/Principal | 01/04/2012 |
| AIMMUNE THERAPEUTICS, INC. | Chief Executive Officer | - |
Formation de Andrew Oxtoby
| Purdue University | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| Entreprise privées | 4 |
|---|---|
Aimmune Therapeutics, Inc.
 Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
Chinook Therapeutics, Inc.
 Chinook Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA. | Health Technology |
| Damien Center | |
Lilly Nederland Holding BV
Lilly Nederland Holding BV Financial ConglomeratesFinance Part of Eli Lilly & Co., Lilly Nederland Holding BV provides investment services. The private company is based in Utrecht, Netherlands. | Finance |
